Virtual Webinar
Identifying and validating effective cancer targets is a critical step in the development of next-generation therapies. In this webinar from Eclipsebio and Active Motif, our experts shared powerful sequencing-based strategies for accelerating cancer target discovery and validation.Dr. Wayne Doyle, Head of Platform at Eclipsebio, demonstrated how transcriptomic insights can drive cancer drug development from initial target discovery to empirical validation. Dr. Michael Garbati, Epigenetics Services Scientist at Active Motif, presented on how multiome analysis can uncover cell subpopulations in cancer samples that may otherwise go undetected.
Summary
Purpose:
Discover how next-generation sequencing powers cancer drug discovery
Presenters:
Dr. Wayne Doyle (Head of Platform, Eclipsebio) and Dr. Michael Garbati (Senior Scientist, Active Motif)
Date:
04 / 17 / 25